Benefit–Risk Assessment of mRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era.

MLA

Kitano, Taito, et al. “Benefit–Risk Assessment of MRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era.” Journal of the Pediatric Infectious Diseases Society, vol. 13, no. 2, Feb. 2024, pp. 129–35. EBSCOhost, https://doi.org/10.1093/jpids/piae002.

APA

Kitano, T., Salmon, D. A., Dudley, M. Z., Thompson, D. A., & Engineer, L. (2024). Benefit–Risk Assessment of mRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era. Journal of the Pediatric Infectious Diseases Society, 13(2), 129–135. https://doi.org/10.1093/jpids/piae002

Chicago

Kitano, Taito, Daniel A Salmon, Matthew Z Dudley, David A Thompson, and Lilly Engineer. 2024. “Benefit–Risk Assessment of MRNA COVID-19 Vaccines in Children Aged 6 Months to 4 Years in the Omicron Era.” Journal of the Pediatric Infectious Diseases Society 13 (2): 129–35. doi:10.1093/jpids/piae002.